Hansoh was established in Jiangsu ，China.
We launched our first GMP manufacturing facility in Lianyungang, Jiangsu Province and commenced production of solid oral formulations.
We were recognized as a Key High and New-Technology Enterprise of the National Torch Program.
We obtained Chinese GMP certifications for our production of large volume parenteral solutions.
Our active pharmaceutical ingredient, vinorelbine tartrate, was approved by the U.S. FDA.
We ranked top 20 in the 2005 Forbes list of Chinese enterprises with potential.
We received approval to establish a Post-doctoral Program Workstation by the Ministry of Personnel and the National Post-doctoral Management Committee of China.
We were certified as a National Enterprise Technology Center.
We were awarded with the State Science and Technology Award (second prize)
Our core product, Zefei, was approved by the U.S. FDA.
We obtained updated versions of Chinese GMP certifications for all our production lines and manufacturing permits for each of our in-house manufactured pharmaceutical products and active pharmaceutical ingredients.
[Mailingda] (morinidazole sodium chlorider injection) (our self-developed latest generation nitroimidazde-class antibiotic) was approved for sale in China as Category 1.1 innovative drug.
We were once again awarded with the State Science and Technology Award (second prize).
We were recognized as an Intellectual Property Advantageous Enterprise by the State Intellectual Property Office of China.
We were recognized as an Intellectual Property Exemplary Enterprise by the State Intellectual Property Office of China.
Our product [Oulanning] (olanzapine tablets) received China Patent Excellence Award from the State Intellectual Property Office of China.
Our product [Xinwei] (imatinib mesylate tablets) received the first prize for the Advancement of Science and Technology from the All-China Federation of Industry & Commerce.
Our core product, Pulaile (pemetrexed disodium for injection), was approved by the PMDA.
We were recognized as one of the “Top 100 Chinese Pharmaceutical Manufacturing Enterprises” by the All-China Federation of Industry & Commerce.
We were recognized as one of the “Top 100 Most Powerful Chinese Chemical and Pharmaceutical Industrial Enterprises in 2017”, “Chinese Chemical and Pharmaceutical Industry Innovative and Excellent Enterprises in 2017” and “Chinese Chemical and Pharmaceutical Industry Excellent Integration Enterprises in 2017” by the China Pharmaceutical Industry Association.
Our product [Oulanning] (olanzapine tablets) was recognized as a Famous Chinese Trademark by the Trademark Office of the State Administration for Industry & Commerce of China.
Our product [Xinwei] (imatinib mesylate tablets) received the China Patent Excellence Award from the State Intellectual Property Office of the PRC.
We were recognized as a “Jiangsu Province Quality Credit AAA Industrial Enterprises” in 2017 by the Jiangsu Municipal Bureau of Quality and Technical Supervision.
We received the “2017 Jiangsu Provincial Governor Quality Award” from the People’s Government of Jiangsu Province.
We ranked 2nd for “R&D-driven pharmaceutical companies in China” in 2018
Fulaimei (Polyethylene Glycol Loxenatide for Injection) received approval for sales in China as a Category 1.1 innovative drug
Hansoh Xinfu® (Flumatinib Mesylate Tablets), China's first independently developed second-generation innovative drug for chronic myeloid leukemia, was launched.
We were successfully listed on the Hong Kong Stock Exchange (listing vehicle: Hansoh Pharmaceutical; stock code: HK.3692), embarking on a new journey of development.
Ameile® (Ametinib Mesylate Tablets) independently developed by Hansoh Pharmaceutical, China's first original third-generation EGFR-TKI innovative drug, was approved for marketing, used for the treatment of non-small cell lung cancer.
Mailingda® (Morinidazole and Sodium Chloride Injection), a Class 1 innovative drug, was granted China Patent Excellence Award by China National Intellectual Property Administration.
